4.6 Review

Current Data and New Insights into the Genetic Factors of Atherogenic Dyslipidemia Associated with Metabolic Syndrome

期刊

DIAGNOSTICS
卷 13, 期 14, 页码 -

出版社

MDPI
DOI: 10.3390/diagnostics13142348

关键词

atherogenic dyslipidemia; metabolic syndrome; cholesterol; triglyceride; genetic risk factors; GWAS

向作者/读者索取更多资源

Atherogenic dyslipidemia is a critical component of metabolic syndrome and is influenced by genetic factors. Genetic studies, including candidate gene-based association studies and genome-wide association studies, have revealed the genetic heterogeneity of atherogenic dyslipidemia. However, many genetic factors are still unknown. Future research should focus on identifying new genes and their molecular mechanisms, which can lead to the development of innovative therapies. Additionally, the use of polygenic risk scores and biomarkers can help identify individuals at risk and guide personalized preventive measures and therapy.
Atherogenic dyslipidemia plays a critical role in the development of metabolic syndrome (MetS), being one of its major components, along with central obesity, insulin resistance, and hypertension. In recent years, the development of molecular genetics techniques and extended analysis at the genome or exome level has led to important progress in the identification of genetic factors (heritability) involved in lipid metabolism disorders associated with MetS. In this review, we have proposed to present the current knowledge related to the genetic etiology of atherogenic dyslipidemia, but also possible challenges for future studies. Data from the literature provided by candidate gene-based association studies or extended studies, such as genome-wide association studies (GWAS) and whole exome sequencing (WES,) have revealed that atherogenic dyslipidemia presents a marked genetic heterogeneity (monogenic or complex, multifactorial). Despite sustained efforts, many of the genetic factors still remain unidentified (missing heritability). In the future, the identification of new genes and the molecular mechanisms by which they intervene in lipid disorders will allow the development of innovative therapies that act on specific targets. In addition, the use of polygenic risk scores (PRS) or specific biomarkers to identify individuals at increased risk of atherogenic dyslipidemia and/or other components of MetS will allow effective preventive measures and personalized therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据